Global Rotavirus Vaccines Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Rotavirus Vaccines Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Rotavirus vaccine is a vaccine used to protect against rotavirus infections, which are the leading cause of severe diarrhea among young children. The vaccines prevent 15–34% of severe diarrhea in the developing world and 37–96% of severe diarrhea in the developed world. The vaccines decrease the risk of death among young children due to diarrhea. Immunizing babies decreases rates of disease among older people and those who have not been immunized.
The World Health Organization (WHO) recommends that rotavirus vaccine be included in national routine vaccinations programs, especially in areas where the disease is common. This should be done along with promoting breastfeeding, handwashing, clean water and good sanitation. It is given by mouth and requires two or three doses. It should be given starting around six weeks of age.
The vaccines are safe. This includes their use in people with HIV/AIDS. An earlier vaccine that is no longer used was linked to intussusception, but the current versions are not clearly linked. Due to a potential risk they are not recommended in babies who have had intussusception. The vaccines are made from weakened rotavirus.
The vaccine first became available in the United States in 2006. It is on the World Health Organization's List of Essential Medicines, the most effective and safe medicines needed in a health system. The wholesale cost in the developing world is between US$6.96 and $20.66 per dose as of 2014.In the United States it is more than US$200. As of 2013 there are two types of vaccine available globally, Rotarix and RotaTeq. Others are used in some countries.
Rotavirus Vaccines report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Rotavirus Vaccines market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Adult and Pediatric are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Rotavirus Vaccines industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Rotavirus Vaccines key manufacturers include Bharat Biotech, Merck & Co., Inc, GlaxoSmithKline plc, Lanzhou Institute of Biological and Bharat Biotech International Limited, etc. Bharat Biotech, Merck & Co., Inc, GlaxoSmithKline plc are top 3 players and held % sales share in total in 2022.
Rotavirus Vaccines can be divided into Rotarix, RotaTeq, Rotavac and Rotavin-M1, etc. Rotarix is the mainstream product in the market, accounting for % sales share globally in 2022.
Rotavirus Vaccines is widely used in various fields, such as Adult and Pediatric, etc. Adult provides greatest supports to the Rotavirus Vaccines industry development. In 2022, global % sales of Rotavirus Vaccines went into Adult filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Rotavirus Vaccines market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
Bharat Biotech
Merck & Co., Inc
GlaxoSmithKline plc
Lanzhou Institute of Biological
Bharat Biotech International Limited
Segment by Type
Rotarix
RotaTeq
Rotavac
Rotavin-M1
Lanzhou lamb
Others
Adult
Pediatric
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Rotavirus Vaccines market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Rotavirus Vaccines, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Rotavirus Vaccines industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Rotavirus Vaccines in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Rotavirus Vaccines introduction, etc. Rotavirus Vaccines Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Rotavirus Vaccines market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.
The World Health Organization (WHO) recommends that rotavirus vaccine be included in national routine vaccinations programs, especially in areas where the disease is common. This should be done along with promoting breastfeeding, handwashing, clean water and good sanitation. It is given by mouth and requires two or three doses. It should be given starting around six weeks of age.
The vaccines are safe. This includes their use in people with HIV/AIDS. An earlier vaccine that is no longer used was linked to intussusception, but the current versions are not clearly linked. Due to a potential risk they are not recommended in babies who have had intussusception. The vaccines are made from weakened rotavirus.
The vaccine first became available in the United States in 2006. It is on the World Health Organization's List of Essential Medicines, the most effective and safe medicines needed in a health system. The wholesale cost in the developing world is between US$6.96 and $20.66 per dose as of 2014.In the United States it is more than US$200. As of 2013 there are two types of vaccine available globally, Rotarix and RotaTeq. Others are used in some countries.
Rotavirus Vaccines report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Rotavirus Vaccines market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Adult and Pediatric are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Rotavirus Vaccines industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Rotavirus Vaccines key manufacturers include Bharat Biotech, Merck & Co., Inc, GlaxoSmithKline plc, Lanzhou Institute of Biological and Bharat Biotech International Limited, etc. Bharat Biotech, Merck & Co., Inc, GlaxoSmithKline plc are top 3 players and held % sales share in total in 2022.
Rotavirus Vaccines can be divided into Rotarix, RotaTeq, Rotavac and Rotavin-M1, etc. Rotarix is the mainstream product in the market, accounting for % sales share globally in 2022.
Rotavirus Vaccines is widely used in various fields, such as Adult and Pediatric, etc. Adult provides greatest supports to the Rotavirus Vaccines industry development. In 2022, global % sales of Rotavirus Vaccines went into Adult filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Rotavirus Vaccines market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
Bharat Biotech
Merck & Co., Inc
GlaxoSmithKline plc
Lanzhou Institute of Biological
Bharat Biotech International Limited
Segment by Type
Rotarix
RotaTeq
Rotavac
Rotavin-M1
Lanzhou lamb
Others
Segment by Application
Adult
Pediatric
Segment by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Rotavirus Vaccines market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Rotavirus Vaccines, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Rotavirus Vaccines industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Rotavirus Vaccines in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Rotavirus Vaccines introduction, etc. Rotavirus Vaccines Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Rotavirus Vaccines market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices